Literature DB >> 2114236

Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes.

C H Follmer1, T J Colatsky.   

Abstract

Block of the delayed rectifier potassium current, IK, by the class IC antiarrhythmic agent, flecainide, and by the novel selective class III antiarrhythmic agent, E-4031, were compared in isolated cat ventricular myocytes using the single suction-pipette, voltage-clamp technique. Flecainide (10 microM) markedly reduced IK elicited on depolarization steps to plateau voltages (+10 mV) and nearly completely blocked the "tail currents" elicited on repolarization to -40 mV (93 +/- 4% block at +40 mV, n = 3). E-4031 (1 microM) produced similar effects (96 +/- 3% block at +40 mV, n = 3). Slow voltage ramps from -100 to +40 mV confirmed inward rectifying properties of IK and showed that flecainide and E-4031 have no effects on the background potassium current, IK1. Thus, the results demonstrate that block of IK is a common feature of flecainide and E-4031. IK block by E-4031 most likely underlies the drug's potent class III antiarrhythmic properties. On the other hand, flecainide block of IK during an action potential would tend to prolong repolarization, but this effect may be obscured by concomitant block of plateau Na+ channels to produce little or no change in action potential duration, consistent with its class IC classification.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114236     DOI: 10.1161/01.cir.82.1.289

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes.

Authors:  H B Nuss; E Marbán; D C Johns
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

2.  Rapidly and slowly activating components of delayed rectifier K(+) current in guinea-pig sino-atrial node pacemaker cells.

Authors:  Hiroshi Matsuura; Tsuguhisa Ehara; Wei-Guang Ding; Mariko Omatsu-Kanbe; Takahiro Isono
Journal:  J Physiol       Date:  2002-05-01       Impact factor: 5.182

3.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.

Authors:  Hugh Clements-Jewery; Gajen Sunthar Kanaganayagam; Ruchi Kabra; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

5.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

6.  Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers.

Authors:  T Yang; C Prakash; D M Roden; D J Snyders
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

7.  Voltage-dependent potassium currents in feline sino-atrial node myocytes.

Authors:  Iván A Aréchiga-Figueroa; Martín Rodríguez-Martínez; José A Sánchez-Chapula
Journal:  Pflugers Arch       Date:  2011-06-23       Impact factor: 3.657

8.  Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration.

Authors:  C Lengyel; N Iost; L Virág; A Varró; D A Lathrop; J G Papp
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

9.  Effects of K+ channel blockers on inwardly and outwardly rectifying whole-cell K+ currents in sheep parotid secretory cells.

Authors:  T Ishikawa; D I Cook
Journal:  J Membr Biol       Date:  1993-04       Impact factor: 1.843

10.  Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.

Authors:  Niels Voigt; Nadiia Rozmaritsa; Anne Trausch; Thomasz Zimniak; Torsten Christ; Erich Wettwer; Klaus Matschke; Dobromir Dobrev; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.